These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. Stahl SM; Grady MM; Moret C; Briley M CNS Spectr; 2005 Sep; 10(9):732-47. PubMed ID: 16142213 [TBL] [Abstract][Full Text] [Related]
12. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Wong DT; Bymaster FP Prog Drug Res; 2002; 58():169-222. PubMed ID: 12079200 [TBL] [Abstract][Full Text] [Related]
13. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Puech A; Montgomery SA; Prost JF; Solles A; Briley M Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045 [TBL] [Abstract][Full Text] [Related]
14. Milnacipran, a new specific serotonin and noradrenaline reuptake inhibitor. Boyer P; Briley M Drugs Today (Barc); 1998 Aug; 34(8):709-20. PubMed ID: 14988777 [TBL] [Abstract][Full Text] [Related]
15. The Role of Metabolites of Antidepressants in the Treatment of Depression. Rudorfer MV; Potter WZ CNS Drugs; 1997 Apr; 7(4):273-312. PubMed ID: 27520753 [TBL] [Abstract][Full Text] [Related]
16. Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan. Higuchi T; Briley M Neuropsychiatr Dis Treat; 2007 Feb; 3(1):41-58. PubMed ID: 19300537 [TBL] [Abstract][Full Text] [Related]